Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128499) titled 'An exploratory study of Trilaciclib for the primary prevention of hematologic toxicity events in neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic cancer' on July 21.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huashan Hospital, Fudan University

Condition: pancreatic cancer

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-31

Target Sample Size: Experimental group:33;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=333804

Disclaimer: Curated by HT Syndication....